Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research
mi
from
Carlsbad, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research
mi
from
Carlsbad, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Institute
mi
from
Newport Beach, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research
mi
from
Santa Rosa, CA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Colorado Springs Family Practice
mi
from
Colorado Springs, CO
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Colorado Springs Family Practice
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Colorado Springs Health Partners, Pc
mi
from
Colorado Springs, CO
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Colorado Springs Health Partners, Pc
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Clinical trials of the Rockies, Inc.
mi
from
Denver, CO
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Clinical trials of the Rockies, Inc.
mi
from
Denver, CO
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Chase Medical Research, LLC
mi
from
Hamden, CT
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Chase Medical Research, LLC
mi
from
Hamden, CT
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Indago Research & Health Center, Inc.
mi
from
Hialeah, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Indago Research & Health Center, Inc.
mi
from
Hialeah, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Meridien Research, Inc.
mi
from
Maitland, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Meridien Research, Inc.
mi
from
Maitland, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Veritas Research Corp
mi
from
Miami Lakes, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Veritas Research Corp
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Ocean Blue Medical Research Center, Inc.
mi
from
Miami Springs, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Ocean Blue Medical Research Center, Inc.
mi
from
Miami Springs, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Prestige Clinical Research
mi
from
Miami, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Prestige Clinical Research
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Florida Medical Center and Research Inc.
mi
from
Miami, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Florida Medical Center and Research Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
The Core Research Associates
mi
from
Miami, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
The Core Research Associates
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Harmony Medical Research Institute, Inc
mi
from
North Miami Beach, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Harmony Medical Research Institute, Inc
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Pinellas Park, FL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Columbus Regional Research Institute
mi
from
Columbus, GA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Columbus Regional Research Institute
mi
from
Columbus, GA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Urban Family Practice Associates
mi
from
Marietta, GA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Urban Family Practice Associates
mi
from
Marietta, GA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Harbin Clinic
mi
from
Rome, GA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Harbin Clinic
mi
from
Rome, GA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Pinnacle Trials Inc.
mi
from
Stockbridge, GA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Pinnacle Trials Inc.
mi
from
Stockbridge, GA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Evanston Premier Healthcare Research LLC
mi
from
Evanston, IL
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Evanston Premier Healthcare Research LLC
mi
from
Evanston, IL
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Synexus - Clinical Research Advantage, Inc.
mi
from
Evansville, IN
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Synexus - Clinical Research Advantage, Inc.
mi
from
Evansville, IN
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Synexus - US
mi
from
Evansville, IN
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Synexus - US
mi
from
Evansville, IN
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Council Bluffs, IA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates
mi
from
Newton, KA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates
mi
from
Newton, KA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Continuum Health Care
mi
from
Overland Park, KA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Continuum Health Care
mi
from
Overland Park, KA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Beacon Clinical Research
mi
from
Quincy, MA
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Beacon Clinical Research
mi
from
Quincy, MA
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Michigan Head Pain & Neurological Institute
mi
from
Ann Arbor, MI
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Michigan Head Pain & Neurological Institute
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Edina, MN
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Edina, MN
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Saint Louis, MO
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Quality Clinical Research, Inc.
mi
from
Omaha, NE
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Quality Clinical Research, Inc.
mi
from
Omaha, NE
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Meridian Clinical Research
mi
from
Omaha, NE
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Meridian Clinical Research
mi
from
Omaha, NE
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Diagnostic Center of Medicine
mi
from
Henderson, NV
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Diagnostic Center of Medicine
mi
from
Henderson, NV
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Rita B. Chuang, MD LLC
mi
from
Henderson, NV
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Rita B. Chuang, MD LLC
mi
from
Henderson, NV
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Hassman Research Institute
mi
from
Berlin, NJ
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Hassman Research Institute
mi
from
Berlin, NJ
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Bio Behavioral Health
mi
from
Toms River, NJ
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Bio Behavioral Health
mi
from
Toms River, NJ
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
CNS Research Science, Inc.
mi
from
Jamaica, NY
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
CNS Research Science, Inc.
mi
from
Jamaica, NY
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
PMG Research of Cary
mi
from
Cary, NC
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
PMG Research of Cary
mi
from
Cary, NC
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Akron, OH
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Akron, OH
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Synexus-US
mi
from
Cincinnati, OH
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Synexus-US
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Synexus - US
mi
from
Columbus, OH
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Synexus - US
mi
from
Columbus, OH
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Oklahoma City Clinic
mi
from
Edmond, OK
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Oklahoma City Clinic
mi
from
Edmond, OK
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Oklahoma City Clinic
mi
from
Midwest City, OK
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Oklahoma City Clinic
mi
from
Midwest City, OK
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Lynn Institute of Norman
mi
from
Norman, OK
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Lynn Institute of Norman
mi
from
Norman, OK
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Oklahoma City Clinic
mi
from
Oklahoma City, OK
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Oklahoma City Clinic
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated:  12/31/1969
Summit Research Network
mi
from
Portland, OR
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Status: Enrolling
Updated: 12/31/1969
Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials